1267. Nonventilator Hospital Acquired Pneumonia (NV-HAP) Prevention Initiative in Colombia - Bogotá
Session: Poster Abstract Session: Healthcare Epidemiology: Outbreaks
Friday, October 5, 2018
Room: S Poster Hall
Background: Pneumonia is the second most common healthcare-associated infection worldwide. Non ventilator - Hospital Acquired Pneumonia (NV-HAP) affects more people than VAP, has a comparable mortality rate (18.7% vs 18.9%), and has higher total costs ($156 million vs $86 million), respectively. The objective of this study was to describe the result of the implementation of a bundle of measures for the prevention of NV-HAP in adult patients in a University Hospital in Colombia.

Methods: Descriptive study. In a period of 2 years, a care bundle for prevention of NV-HAP was implemented in adult patients in a university hospital that consisted of: 1. identification of patients at risk (patients over 60 years of age, or with altered consciousness, or swallowing disorder, or patients with tracheostomy), 2. Marking the patient with a sticker on the head of the bed and, 3. implementation of the following measures: head of the bed elevation to 30°-45, oral care every 12 hours, chlorhexidine oral rinse decontamination every 12 hours and aspiration of secretions as needed. In the first six months, training was carried out for all staff, the monthly adherence to the strategy was measured.

Results: During 2016, 1045 patients were included, with 10.011 observations, bundle adherence during the first year was 33%. in the second year, 1400 patiens were included, with 13198 observations, the bundle adherence increased to 90% throughout the hospital. The rate of NV-HAP decreased from 4.2 (96 cases) to 3.4 (89 cases) per 1000 patient days, in the second year compared to the previous intervention year.

Conclusion: The strategy of prevention of NV-HAP decreased the cases of nosocomial pneumonia in a university hospital, through the education a high adherence to the strategy was achieved. Studies with a better design should be done to confirm the findings.

Sandra Valderrama, Specialist in Infectious Diseases1, Claudia Janneth Linares Miranda, NP2, Maria Juliana Soto, MD3, Estefania Mckinley, MD3, Juan Pablo Morcillo, MD4, Juan Pablo Alarcon, MD4, Angela Patricia Gonzalez, NP1 and Leidy Gamba, Nurse1, (1)Infectious Diseases, Hospital Universitario San Ignacio, Bogotá, Colombia, (2)Infectious Diseases, Hospital Universitario San Ignacio, BOGOTA, Colombia, (3)Pontificia Universidad Javeriana, Bogota, Colombia, (4)Pontificia Universidad Javeriana, BOGOTA, Colombia

Disclosures:

S. Valderrama, None

C. J. Linares Miranda, None

M. J. Soto, None

E. Mckinley, None

J. P. Morcillo, None

J. P. Alarcon, None

A. P. Gonzalez, None

L. Gamba, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.